Scientists test 'Off-the-Shelf' cell therapy for tough blood cancers
NCT ID NCT06325748
Summary
This is a first-in-human study to find a safe dose of a new, ready-made cell therapy called SENTI-202. It is for adults with advanced blood cancers, like AML or MDS, that have come back or stopped responding to standard treatments. The main goals are to check the safety of the treatment and see if it can help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML/MDS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Methodist Healthcare
San Antonio, Texas, 78229, United States
-
Peter MacCallum Cancer Center
Melbourne, Victoria, 3000, Australia
-
Royal Prince Alfred Hospital
Camperdown, New South Wales, 2050, Australia
-
TriStar Bone Marrow Transplant
Nashville, Tennessee, 37203, United States
-
UCLA Medical Center
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.